Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on QOL and Resource Utilization, of Injectafer® vs. IV Iron Standard of Care for the Treatment of IDA in an Infusion Center

NCT01950247 is registered in ClinicalTrials.gov with American Regent, Inc. as lead sponsor.

NCT NCT01950247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01950247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on QOL and Resource Utilization, of Injectafer® vs. IV Iron Standard of Care for the Treatment of IDA in an Infusion Center
Lead sponsor
American Regent, Inc.
Phase
Phase 4
Overall status
Completed
Start date
August 15, 2013
Completion date
June 30, 2015
Enrollment
1,025 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

iron deficiency anemia (ida)